COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART
1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sun, Yi-Lan [verfasserIn] Hu, Shen-Jiang [verfasserIn] Wang, Li-Hong [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Science Pty ; 2005 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2005 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Clinical and experimental pharmacology and physiology - Oxford [u.a.] : Wiley-Blackwell, 1974, 32(2005), 7, Seite 0 |
| Übergeordnetes Werk: |
volume:32 ; year:2005 ; number:7 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1440-1681.2005.04230.x |
|---|
| Katalog-ID: |
NLEJ242565875 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242565875 | ||
| 003 | DE-627 | ||
| 005 | 20230505183717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2005 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1440-1681.2005.04230.x |2 doi | |
| 035 | |a (DE-627)NLEJ242565875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Sun, Yi-Lan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART |
| 264 | 1 | |a Oxford, UK |b Blackwell Science Pty |c 2005 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a 1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression. | ||
| 533 | |d 2005 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2005|||||||||| | ||
| 650 | 4 | |a carvedilol | |
| 700 | 1 | |a Hu, Shen-Jiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Li-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Ying |4 oth | |
| 700 | 1 | |a Zhou, Jian-Ying |4 oth | |
| 773 | 0 | 8 | |i In |t Clinical and experimental pharmacology and physiology |d Oxford [u.a.] : Wiley-Blackwell, 1974 |g 32(2005), 7, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243927150 |w (DE-600)2020033-X |x 1440-1681 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2005 |g number:7 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1440-1681.2005.04230.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2005 |e 7 |h 0 | ||
| author_variant |
y l s yls s j h sjh l h w lhw |
|---|---|
| matchkey_str |
article:14401681:2005----::oprsnfoadihoeocreioorsoainfadafntoadacuhnl |
| hierarchy_sort_str |
2005 |
| publishDate |
2005 |
| allfields |
10.1111/j.1440-1681.2005.04230.x doi (DE-627)NLEJ242565875 DE-627 ger DE-627 rakwb Sun, Yi-Lan verfasserin aut COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART Oxford, UK Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| carvedilol Hu, Shen-Jiang verfasserin aut Wang, Li-Hong verfasserin aut Hu, Ying oth Zhou, Jian-Ying oth In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 32(2005), 7, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:32 year:2005 number:7 pages:0 http://dx.doi.org/10.1111/j.1440-1681.2005.04230.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2005 7 0 |
| spelling |
10.1111/j.1440-1681.2005.04230.x doi (DE-627)NLEJ242565875 DE-627 ger DE-627 rakwb Sun, Yi-Lan verfasserin aut COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART Oxford, UK Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| carvedilol Hu, Shen-Jiang verfasserin aut Wang, Li-Hong verfasserin aut Hu, Ying oth Zhou, Jian-Ying oth In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 32(2005), 7, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:32 year:2005 number:7 pages:0 http://dx.doi.org/10.1111/j.1440-1681.2005.04230.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2005 7 0 |
| allfields_unstemmed |
10.1111/j.1440-1681.2005.04230.x doi (DE-627)NLEJ242565875 DE-627 ger DE-627 rakwb Sun, Yi-Lan verfasserin aut COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART Oxford, UK Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| carvedilol Hu, Shen-Jiang verfasserin aut Wang, Li-Hong verfasserin aut Hu, Ying oth Zhou, Jian-Ying oth In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 32(2005), 7, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:32 year:2005 number:7 pages:0 http://dx.doi.org/10.1111/j.1440-1681.2005.04230.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2005 7 0 |
| allfieldsGer |
10.1111/j.1440-1681.2005.04230.x doi (DE-627)NLEJ242565875 DE-627 ger DE-627 rakwb Sun, Yi-Lan verfasserin aut COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART Oxford, UK Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| carvedilol Hu, Shen-Jiang verfasserin aut Wang, Li-Hong verfasserin aut Hu, Ying oth Zhou, Jian-Ying oth In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 32(2005), 7, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:32 year:2005 number:7 pages:0 http://dx.doi.org/10.1111/j.1440-1681.2005.04230.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2005 7 0 |
| allfieldsSound |
10.1111/j.1440-1681.2005.04230.x doi (DE-627)NLEJ242565875 DE-627 ger DE-627 rakwb Sun, Yi-Lan verfasserin aut COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART Oxford, UK Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier 1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| carvedilol Hu, Shen-Jiang verfasserin aut Wang, Li-Hong verfasserin aut Hu, Ying oth Zhou, Jian-Ying oth In Clinical and experimental pharmacology and physiology Oxford [u.a.] : Wiley-Blackwell, 1974 32(2005), 7, Seite 0 Online-Ressource (DE-627)NLEJ243927150 (DE-600)2020033-X 1440-1681 nnns volume:32 year:2005 number:7 pages:0 http://dx.doi.org/10.1111/j.1440-1681.2005.04230.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 32 2005 7 0 |
| source |
In Clinical and experimental pharmacology and physiology 32(2005), 7, Seite 0 volume:32 year:2005 number:7 pages:0 |
| sourceStr |
In Clinical and experimental pharmacology and physiology 32(2005), 7, Seite 0 volume:32 year:2005 number:7 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
carvedilol |
| isfreeaccess_bool |
false |
| container_title |
Clinical and experimental pharmacology and physiology |
| authorswithroles_txt_mv |
Sun, Yi-Lan @@aut@@ Hu, Shen-Jiang @@aut@@ Wang, Li-Hong @@aut@@ Hu, Ying @@oth@@ Zhou, Jian-Ying @@oth@@ |
| publishDateDaySort_date |
2005-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243927150 |
| id |
NLEJ242565875 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242565875</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505183717.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1440-1681.2005.04230.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242565875</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Yi-Lan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Pty</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2005</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2005||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">carvedilol</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Shen-Jiang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Li-Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Ying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Jian-Ying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Clinical and experimental pharmacology and physiology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1974</subfield><subfield code="g">32(2005), 7, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927150</subfield><subfield code="w">(DE-600)2020033-X</subfield><subfield code="x">1440-1681</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:32</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1440-1681.2005.04230.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">32</subfield><subfield code="j">2005</subfield><subfield code="e">7</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Sun, Yi-Lan |
| spellingShingle |
Sun, Yi-Lan misc carvedilol COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART |
| authorStr |
Sun, Yi-Lan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243927150 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1440-1681 |
| topic_title |
COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART carvedilol |
| publisher |
Blackwell Science Pty |
| publisherStr |
Blackwell Science Pty |
| topic |
misc carvedilol |
| topic_unstemmed |
misc carvedilol |
| topic_browse |
misc carvedilol |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
y h yh j y z jyz |
| hierarchy_parent_title |
Clinical and experimental pharmacology and physiology |
| hierarchy_parent_id |
NLEJ243927150 |
| hierarchy_top_title |
Clinical and experimental pharmacology and physiology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243927150 (DE-600)2020033-X |
| title |
COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART |
| ctrlnum |
(DE-627)NLEJ242565875 |
| title_full |
COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART |
| author_sort |
Sun, Yi-Lan |
| journal |
Clinical and experimental pharmacology and physiology |
| journalStr |
Clinical and experimental pharmacology and physiology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2005 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Sun, Yi-Lan Hu, Shen-Jiang Wang, Li-Hong |
| container_volume |
32 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sun, Yi-Lan |
| doi_str_mv |
10.1111/j.1440-1681.2005.04230.x |
| author2-role |
verfasserin |
| title_sort |
comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart |
| title_auth |
COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART |
| abstract |
1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression. |
| abstractGer |
1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression. |
| abstract_unstemmed |
1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
7 |
| title_short |
COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART |
| url |
http://dx.doi.org/10.1111/j.1440-1681.2005.04230.x |
| remote_bool |
true |
| author2 |
Hu, Shen-Jiang Wang, Li-Hong Hu, Ying Zhou, Jian-Ying |
| author2Str |
Hu, Shen-Jiang Wang, Li-Hong Hu, Ying Zhou, Jian-Ying |
| ppnlink |
NLEJ243927150 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1111/j.1440-1681.2005.04230.x |
| up_date |
2024-07-06T02:25:08.030Z |
| _version_ |
1803794732056313856 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242565875</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505183717.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1440-1681.2005.04230.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242565875</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Yi-Lan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COMPARISON OF LOW and HIGH DOSES OF CARVEDILOL ON RESTORATION OF CARDIAC FUNCTION and CALCIUM-HANDLING PROTEINS IN RAT FAILING HEART</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Pty</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">1. The β-adrenoceptor antagonist carvedilol reverses cardiac dysfunction in the failing heart. A recent study showed that β-adrenoceptor antagonists indirectly normalize Ca2+-regulatory proteins. The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear.2. We investigated the change in left ventricular (LV) remodelling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 or 2 mg/kg per day) treatment for 6 weeks. The expression of mRNA and proteins of sarcoplasmic reticulum Ca2+-ATPase (SERCA) and phospholamban (PLB) in cardiomyocytes was also measured.3. There was significant LV remodelling and cardiac contractile dysfunction in MI rats. The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats. After treatment with carvedilol, LV remodelling and cardiac contractile dysfunction were clearly improved. Low-dose carvedilol was better at improving some parameters of LV remodelling and function than the high dose. Carvedilol partially restored the low expression of SERCA (P < 0.05), but had no effect on PLB expression (P > 0.05). Moreover, low-dose carvedilol induced a more significant improvement in SERCA expression than did the high dose (P < 0.05).4. The results of the present study suggest that carvedilol is effective in improving LV remodelling and cardiac contractile dysfunction after MI. This may be related to the normalization of SERCA expression.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2005</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2005||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">carvedilol</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Shen-Jiang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Li-Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Ying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Jian-Ying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Clinical and experimental pharmacology and physiology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1974</subfield><subfield code="g">32(2005), 7, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927150</subfield><subfield code="w">(DE-600)2020033-X</subfield><subfield code="x">1440-1681</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:32</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1440-1681.2005.04230.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">32</subfield><subfield code="j">2005</subfield><subfield code="e">7</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.397253 |